Core Viewpoint - Alterity Therapeutics is actively engaging with investors and the public through a webinar to discuss its developments in neurodegenerative disease treatments, particularly focusing on its lead asset, ATH434 [1][2]. Group 1: Company Overview - Alterity Therapeutics is a clinical stage biotechnology company focused on developing disease-modifying treatments for neurodegenerative diseases [2]. - The company's lead asset, ATH434, has potential applications in treating various Parkinsonian disorders [2]. - Alterity operates from Melbourne, Australia, and San Francisco, California, USA [2]. Group 2: Event Participation - David Stamler, M.D., the CEO of Alterity, will participate in the ShareCafe Hidden Gems webinar on February 2, 2024, for Australian participants and February 1, 2024, for U.S. participants [1]. - The webinar is free to register, and an archived replay will be available after the event [1].

Core Insights - Alterity Therapeutics is focused on developing disease-modifying treatments for neurodegenerative diseases, particularly Multiple System Atrophy (MSA) and Parkinson's disease, with significant milestones achieved in 2023 and plans for 2024 [1][8]. Company Overview - Alterity Therapeutics is a clinical-stage biotechnology company based in Melbourne, Australia, and San Francisco, California, dedicated to treating neurodegenerative diseases [9]. Clinical Trials - The company is conducting two Phase 2 clinical trials: ATH434-201, which completed participant enrollment in November 2023 and will conclude in November 2024, and ATH434-202, which is assessing more advanced MSA patients and will provide preliminary data in the first half of 2024 [4][5]. - ATH434, the lead candidate, is an orally administered agent that redistributes excess iron in the brain, reduces alpha-synuclein protein, and rescues neuronal function, showing potential to treat both MSA and Parkinson's disease [3][8]. Regulatory Designation - ATH434 has received Orphan Drug Designation (ODD) from the U.S. FDA and the European Commission for the treatment of MSA, which provides benefits such as market exclusivity for 7-10 years, tax credits, and protocol assistance [3]. Research and Development - The bioMUSE Natural History study continues to provide valuable insights into MSA, aiding in the design of ongoing clinical trials and enhancing patient selection [6]. - Promising data from a Parkinson's disease primate model demonstrated that ATH434 can reduce symptoms, which supports the ongoing clinical trials [7]. Future Outlook - 2024 is expected to be pivotal for Alterity, with topline data from the ATH434-201 trial anticipated shortly after its completion in November 2024, and preliminary data from the ATH434-202 trial expected in the first half of the year [8].

Exhibit 99.1 Alterity Therapeutics Limited Appendix 4E Audited Financial Report For the year ended 30 June 2023 | --- | --- | |---------------------------------------------|-----------------------------------| | | | | Name of entity | Alterity Therapeutics Limited | | ABN or equivalent company reference | 37 080 699 065 | | Current reporting period | 30 June 2023 | | Corresponding reporting period | 30 June 2022 | Results for announcement to the market | --- | --- | --- | --- | --- | |---------------------- ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington D.C. 20549 Title of each class Trading Symbol Name of each exchange on which registered American Depositary Shares, each representing 600 Ordinary Shares ATHE NASDAQ Capital Market FORM 20-F ☐ REGISTRATION STATEMENT PURSUANT TO SECTION 12(b) OR (g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO ...

Alterity Therapeutics Ltd (NASDAQ:ATHE) Q2 2021 Earnings Conference Call February 25, 2021 5:00 PM ET Company Participants David Stamler - CEO, Chief Medical Officer & SVP, Clinical Development Kathryn Andrews - CFO Conference Call Participants Operator Good morning, and welcome to the Alterity Therapeutics H1 Financial Results and Business update. [Operator Instructions]. Today's call is being recorded. And I'd like to introduce you to our host, Dr. David Stamler, Alterity Therapeutics Chief Executive Offi ...